Elyse Stock
Directeur/Membre du Conseil chez Areteia Therapeutics, Inc.
Postes actifs de Elyse Stock
Sociétés | Poste | Début | Fin |
---|---|---|---|
Areteia Therapeutics, Inc.
Areteia Therapeutics, Inc. BiotechnologyHealth Technology Areteia Therapeutics, Inc. is a clinical stage biotechnology company that focuses on developing and delivering novel inflammation and immunology therapies for respiratory patients. The company is based in Short Hills, NJ, and the CEO of the company is Jorge Bartolome. The company's initial focus is on developing the first potential oral drug for eosinophilic asthma, with its lead drug candidate being dexpramipexole, a first-in-class oral eosinophil maturation inhibitor. Areteia was created by Population Health Partners and Knopp Biosciences, and a syndicate of leading life sciences and strategic investors has committed to investing up to $350 million in series A financing to establish Areteia and advance dexpramipexole through phase III clinical trials. | Directeur/Membre du Conseil | 17/04/2023 | - |
Historique de carrière de Elyse Stock
Anciens postes connus de Elyse Stock
Sociétés | Poste | Début | Fin |
---|---|---|---|
BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | Directeur/Membre du Conseil | - | 03/10/2022 |
Directeur Technique/Scientifique/R&D | 01/08/2019 | 03/10/2022 | |
Corporate Officer/Principal | 21/06/2017 | 01/08/2019 |
Formation de Elyse Stock
New York University School of Medicine | Doctorate Degree |
Statistiques
Internationale
Etats-Unis | 3 |
Opérationnelle
Director/Board Member | 2 |
Chief Tech/Sci/R&D Officer | 1 |
Corporate Officer/Principal | 1 |
Sectorielle
Health Technology | 3 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 2 |
---|---|
Biohaven Pharmaceutical Holding Co. Ltd.
Biohaven Pharmaceutical Holding Co. Ltd. Pharmaceuticals: MajorHealth Technology Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT. | Health Technology |
Areteia Therapeutics, Inc.
Areteia Therapeutics, Inc. BiotechnologyHealth Technology Areteia Therapeutics, Inc. is a clinical stage biotechnology company that focuses on developing and delivering novel inflammation and immunology therapies for respiratory patients. The company is based in Short Hills, NJ, and the CEO of the company is Jorge Bartolome. The company's initial focus is on developing the first potential oral drug for eosinophilic asthma, with its lead drug candidate being dexpramipexole, a first-in-class oral eosinophil maturation inhibitor. Areteia was created by Population Health Partners and Knopp Biosciences, and a syndicate of leading life sciences and strategic investors has committed to investing up to $350 million in series A financing to establish Areteia and advance dexpramipexole through phase III clinical trials. | Health Technology |
- Bourse
- Insiders
- Elyse Stock
- Expérience